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Abstract
Human immunodeficiency virus type 1 (HIV) continues to be one of the most prevalent global health afflictions to
date. The advent and introduction of combined antiretroviral therapy (cART) has made a significant impact on the
course of infection. However, as patients are living longer, many HIV-associated illnesses are becoming prevalent
among the infected population, especially those associated with chronic inflammation. Consistently, HIV-associated
neuroinflammation is believed to be a major catalyst in the development of HIV-associated neurocognitive disorders
(HAND), which are estimated to persist in approximately 50% of infected individuals regardless of cART. This
dramatically underscores the need to develop effective adjunctive therapies capable of controlling this aspect of
the disease, which are currently lacking.
We previously demonstrated that the inflammatory mediator soluble CD40 ligand (sCD40L) is elevated in both
the plasma and cerebrospinal fluid of cognitively impaired infected individuals compared to their non-impaired
infected counterparts. Our group, and others have recently demonstrated that there is an increasing role for this
inflammatory mediator in the pathogenesis of HIV-associated neuroinflammation, thereby identifying this molecule
as a potential therapeutic target for the management of HAND. Platelets are the major source of circulating sCD40L,
and these small cells are increasingly implicated in a multitude of inflammatory disorders, including those
common during HIV infection. Thus, antiplatelet therapies that minimize the release of platelet-derived inflammatory
mediators such as sCD40L are an innovative, non-traditional approach for the treatment of HIV-associated
neuroinflammation, with the potential to benefit other HIV-associated illnesses.
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Introduction
CD40 ligand (CD40L, formally known as CD154) is a
type II membrane glycoprotein of the tumor necrosis
factor (TNF) family that is found on activated T cells, B
cells and platelets [1]. Classically, CD40L is a co-
stimulatory molecule expressed on the surface of acti-
vated CD4 positive T cells. It binds to its receptor, CD40,
on the surface of antigen-presenting cells to induce acti-
vation and enhance the expression of B7 molecules to
promote T cell expansion. In B cells, CD40L binding in-
duces proliferation and immunoglobulin class switching
[1,2], while the absence of CD40L, as in X-linked hyper
IgM syndrome, confers immunosuppression and lack of
immunoglobulin class switching [3,4]. In addition to T
cells, CD40L is also found on the surface of monocytes,
macrophages, endothelial cells and platelets [2]. Cleavage
of CD40L from the surface of cells produces a truncated,
soluble form, sCD40L, which retains biologic activity
and the ability to act as a cytokine [1,5,6]. Based on
cellular distribution studies, platelets are believed to
be almost the sole producers of sCD40L, responsible
for approximately 95% of all sCD40L found in the
plasma [7].
Beyond the co-stimulatory role of CD40L, this medi-
ator also plays an important role in mediating inflamma-
tion. During an innate immune response, cytokines and
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chemokines are released by local cells at the site of in-
sult. Subsequently, these molecules signal to monocytes
to migrate to these areas, thus initiating an inflammatory
response, which aids in wound healing and the clearance
of dead or damaged cells. If there is vessel damage, the
platelets encounter extracellular matrix proteins such as
collagen, which induces the release of hemostatic media-
tors, including sCD40L, from these cells [7]. CD40 is
constitutively expressed on endothelial cells. On ligation
by sCD40L these cells become more conducive to mo-
nocytes that are recruited via a so-called inflammatory
endothelial phenotype [8]. This phenotype has increased
expression of adhesion molecules such as intracellular
adhesion molecule 1 (ICAM-1) and vascular cell adhe-
sion molecule 1 (VCAM-1), and is associated with the
release of additional cytokines and chemoattractants
[8,9]. Once recruited, monocytes can complex with pla-
telets for further activation, or firmly adhere to the
endothelium to extravasate through the vessel and into
the tissue for the clearance of infection.
Inflammation is a delicate process that requires careful
maintenance and balance; hence, dysregulation of this
process can lead to various disease states. Following in-
fection with human immunodeficiency virus type 1
(HIV), immune activation and inflammation are com-
mon, which are the result of both viral replication and
cellular activation, and collectively lead to the release of
a large number of pro-inflammatory mediators termed
HIV effector molecules [10,11]. These host-derived and
viral proteins are thought to be the main culprits re-
sponsible for overstimulating a wide range of cells, both
in the central nervous system (CNS) and in the periph-
ery, which perpetuates inflammation during infection.
This, in turn, leads to the establishment of a chronic in-
flammatory disease state [10]. HIV effector molecules per-
sist despite combined antiretroviral therapy (cART), and
contribute to the development of many HIV-associated ill-
nesses, including HIV-associated neuroinflammation.
CD40L has been implicated previously in HIV-asso-
ciated immune activation and inflammation, as it has
been demonstrated that CD40-CD40L signaling sup-
presses production of the antiviral response protein
interferon α in plasmacytoid dendritic cells, leading to
an increased production of cytokines in peripheral blood
mononuclear cells [12]. Furthermore, this lack of an
interferon α-mediated antiviral response may contribute
to increased opportunistic infections and the immune
reconstitution inflammatory syndrome (IRIS) in some
HIV patients [13]. This further supports the notion that
the establishment of a chronic inflammatory state in
HIV-infected individuals is due to an increase in HIV ef-
fector molecules such as sCD40L, and highlights the po-
tential for identifying candidate HIV effector molecules
as novel therapeutic targets.
CD40L has been implicated in numerous inflamma-
tory conditions, such as cardiovascular disease [2,7], ath-
erosclerosis [14], inflammatory bowel syndrome [15],
fibrosis [16] and many more, in addition to HIV in-
fection [12,13,17]. For example, patients with type 1
diabetes have been found to have elevated levels of cir-
culating sCD40L, which was implicated in stimulating
monocytes to express a more pro-inflammatory pheno-
type [18], further demonstrating a role for this molecule
in the persistence of a chronic inflammatory state. Inter-
estingly, CD40L signaling is also implicated in several
neurodegenerative disorders including cerebral malaria
[19] and Alzheimer’s disease [20,21]. Accordingly, in a
mouse model of Alzheimer’s disease, Tan et al. observed
that mice deficient in CD40L had reduced astrocytosis
and microgliosis compared to mice expressing CD40L
[21]. Collectively, these studies implicate CD40-CD40L
signaling as a potential therapeutic target not only for
persistent inflammatory diseases, but also for neuroin-
flammatory disorders.
In many of these disorders it is believed that the exces-
sive interaction of platelet-derived sCD40L with CD40
on the surface of endothelial cells induces an inflamma-
tory endothelial cell phenotype, as discussed above, and
ultimately aberrant inflammation, tissue infiltration and
cellular damage. Interestingly, increased infiltration of
the CNS by activated leukocytes is widely believed to be
the largest contributing factor in the development of
HIV-associated neuroinflammation, due to the excessive
release of HIV effector molecules within the CNS by
these activated cells, and the development of a prog-
ressively neurotoxic environment [22]. Activation and
dysregulation of brain microvascular endothelial cells
(BMVECs), which form the blood–brain barrier (BBB),
have been reported in the context of HIV and ultimately
result in the deterioration of the barrier, and in turn, fa-
cilitate the recruitment and transmigration of activated
or infected leukocytes through the BBB, exceeding that
which is considered routine [23].
It has recently been purported that sCD40L may have
a larger role than previously thought in the pathogenesis
of HIV-associated neuroinflammation and the subse-
quent development of HIV-associated neurocognitive
disorders (HAND). Our group has observed that plasma
and cerebrospinal fluid concentrations of sCD40L are
elevated in HIV-infected, cognitively impaired individ-
uals [17] compared to infected, non-cognitively impaired
patients. Furthermore, CD40-CD40L signaling has been
implicated in HIV-associated neuroinflammation previ-
ously: Ramirez et al. observed an increase in CD40 ex-
pression on BMVECs from patients who had succumbed
to infection and been diagnosed with HIV encephalitis
compared to BMVECs from control brains [24], indicat-
ing that endothelial cells in patients with HAND-related
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complications are highly responsive to excess amounts
of sCD40L. Consistently, it has been reported that
microglia cells derived from HIV-encephalitic patients
have increased expression of CD40, further demonstra-
ting the involvement of this signaling pathway in these
disorders [25].
Additional studies by our group, using both wild-type
(WT) and CD40L-deficient mice, have recently demon-
strated that excess sCD40L is induced by the HIV Tat
protein in a manner that promotes increased BBB per-
meability and enhanced attachment of monocytes to the
brain microvasculature in vivo [26]. This effect was
found to be mediated by platelet activation, and the sub-
sequent release of sCD40L, since depletion of platelets
in WT mice prior to Tat treatment led to an ameliora-
tion of the Tat-induced BBB permeability, in the same
manner observed in CD40L-deficient animals [26]. While
there are many factors, both host derived and viral, that
orchestrate the breakdown of the BBB during HIV infec-
tion [25,27-30], we observed a drastic effect mediated by
platelet-derived CD40L. Collectively, these results suggest
that the CD40L/CD40 pair has a large role in the progres-
sion of HAND, and provide evidence that excessive plate-
let activation may be contributing to a multitude of other
inflammatory disorders.
Consistent with this notion, there is an expanding view
of the role for platelets in the pathogenesis of HIV, as
they interact with a number of immune cells and con-
tribute to the breadth of pro-inflammatory mediators
found during infection [31]. Aberrant platelet activation
is increasingly recognized as a major contributor to a
number of inflammatory conditions, including athero-
sclerosis, diabetes and arthritis. In the context of HIV, it
has been found that platelets circulate in a more ac-
tivated state within infected individuals [32], and HIV
infection is associated with the release of molecules
known to activate platelets, such as platelet-activating
factor [33]. Ironically, thrombocytopenia is frequently
diagnosed in HIV-infected individuals, suggesting that
the contribution of platelets to HIV-associated illnesses
would be low, given the low numbers of these cells de-
tected in these patients. However, platelet activation in
the periphery is followed by rapid removal of these cells
from circulation, thereby indicating that a low platelet
count follows overstimulation of platelets during HIV in-
fection, followed by their clearance. Furthermore, acti-
vated platelets may be sequestered in cellular aggregates
during HIV infection [34,35], which could also contrib-
ute to decreased detection of these cells in complete
blood cell counts of infected individuals. In line with
this, it has been demonstrated that platelet decline dur-
ing HIV infection is associated with the onset of neuro-
logical impairment [36,37], thus indicating that platelet
activation and their subsequent removal from circulation
precedes the onset of neurological symptoms and has a
large role in the pathogenesis of HAND.
Although the introduction of combination antiretro-
viral therapy (cART) has made a tremendous impact on
the course of HIV as well as HAND, there remains a
critical lack of effective adjunctive therapies for the ma-
nagement of the neuropathological aspect of these di-
seases. With over 50% of cART-receiving patients still
suffering from some form of cognitive impairment [38],
it is clear that this is an area that cannot be ignored. In
general, it is widely believed that one of the largest con-
tributing factors in the initiation of HAND is the break-
down of the BBB, which allows infiltration of the CNS
by activated or infected macrophages that perpetuate
this inflammatory disease. Hence, identifying the under-
lying mechanisms that contribute to this breakdown,
and thus drive the pathogenesis of HAND, would reveal
novel targets for therapeutic intervention. Antiplatelet
therapies that minimize the release of platelet-derived
inflammatory mediators such as sCD40L may therefore
prove to be a worthy avenue of pursuit in identifying
novel treatment strategies for HAND. In addition, given
the involvement of sCD40L in the dysregulation of mul-
tiple immune response mechanisms in the context of
HIV [39,40], this approach may have the added benefit
of modulating both HAND and other HIV-associated in-
flammatory disorders.
Platelets and vascular permeability
Platelets are small, approximately 3 μm, anucleate cells
involved in hemostasis, the process of blood clotting,
and inflammation. Although they do not have a nucleus,
platelets do contain most of the classical cellular compo-
nents, and have the ability to process precursor mRNA
and translate mRNA into proteins [41,42]. Platelets are
the first cells to respond to vascular injury, interacting
with endothelial cells to form a plug over the wound,
and they aid in leukocyte recruitment via the release of
inflammatory mediators [8]. Normal platelet–endothelial
cell interactions at the site of an injury are similar to
those seen in leukocyte rolling; platelets roll along endo-
thelial cells and form loose contacts upon interaction
with selectins on the surface of activated endothelial
cells or with extracellular matrix components such as
collagen or fibrinogen [8,9]. These interactions activate
the platelet and induce firm adhesions through integrins
on both the platelet and the endothelial cell surfaces,
which in turn causes platelet aggregation, cytoskeletal
rearrangement and a signaling cascade that ultimately
leads to the release of cytokines and chemoattractants
from both platelets and endothelial cells [8,43]. This
process is necessary for normal wound healing and
hemostasis; however, as outlined above, dysregulation
or overstimulation of this process can lead to many
Davidson et al. Journal of Neuroinflammation 2013, 10:144 Page 3 of 11
http://www.jneuroinflammation.com/content/10/1/144
inflammatory complications. Similarly, low platelet counts,
or thrombocytopenia, is also cause for alarm, as it can in-
duce hemorrhage. Thus, a delicate balance of stimulation
and attenuation of signaling within these cells is vital for
proper homeostasis.
In the event that this balance is disrupted, via the in-
duction of an excessive inflammatory BMVEC pheno-
type by platelet-derived sCD40L within the plasma of
HIV-infected individuals [17,44], it is plausible that
sCD40L largely contributes to the increased permeability
of the BBB seen during HAND, thereby increasing
monocyte traffic at the BBB and invasion of the CNS by
pro-inflammatory cells [26]. However, this implies a
contradictory role for platelets in vessel integrity during
inflammatory disease. This is an interesting thought
given that the classical role of platelets is to prevent ves-
sel leakage by forming a plug over areas of insult in an
effort to minimize vessel and tissue damage [45]. It is
clear that a basal level of endothelial cell permeability is
necessary for the proper exchange of nutrients, ions and
water, and it allows leukocytes access to injured tissues;
thus, platelets aid in the development of an environment
at the endothelium that is conducive to a modest
amount of vascular permeability. Therefore, upon dys-
regulation of this system, it is likely that aberrant acti-
vation of platelets could intensify this process in a
pathological manner, thereby corroborating the observed
effect that the absence of platelets can ameliorate vascu-
lar permeability in certain circumstances.
As previously mentioned, platelets circulate in a more
activated state within HIV-infected individuals [32,46],
and HIV infection is associated with an increase in
various markers of platelet activation, such as soluble
P-selectin, sCD40L and platelet-monocyte complexes
[17,35,44,46]. Furthermore, HIV is associated with an in-
creased risk of thrombotic complications and vascular
disease, of both the cardiovascular and cerebrovascular
systems [47-50]. Thus, the inflammatory environment
observed during HIV infection seems to support the
dysregulation of platelets: it causes excessive activation
and the subsequent release of sCD40L, and contributes
to vascular permeability, contrary to the classical role of
platelets (Figure 1).
Consistent with this notion, there is an expanding
breadth of knowledge to suggest that platelets play a role
in numerous inflammatory disorders, including those
Figure 1 Working model and overall summary. Upon exposure to HIV effector molecules, both viral and host derived, platelets become
aberrantly activated and release an excess of soluble CD40 ligand (sCD40L). This sCD40L can then bind to its receptor, CD40, on the surface of
brain microvascular endothelial cells (BMVECs), inducing an inflammatory endothelial cell phenotype. Features of this phenotype include
upregulation of cellular adhesion molecules such as P-selectin, ICAM-1 and VCAM-1, as well as the release of the chemoattractant MCP-1.
Subsequently, leukocytes are recruited to the endothelium, where they are able to adhere and migrate through the barrier and into the central
nervous system, thus stimulating a pro-inflammatory, excitotoxic environment. Therefore, inhibition of sCD40L release from platelets via
antiplatelet therapies has the potential to attenuate this process. BMVEC, brain microvascular endothelial cell; cART, combined antiretroviral
therapy; ICAM-1, intracellular adhesion molecule 1; sCD40L, soluble CD40 ligand; VCAM-1, vascular cell adhesion molecule 1.
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that are associated with vascular permeability. Interest-
ingly, Cloutier et al. recently demonstrated that synovial
vascular permeability observed in a murine experimental
arthritis model was abrogated when platelets were de-
pleted prior to the onset of arthritis [51]. The authors
note that this was an unexpected finding due to the clas-
sical role of platelets in vessel maintenance, and may be
the result of the severe inflammatory environment in the
experimental arthritis model and the subsequent over-
stimulation of platelets [51]. Similarly, several reports
note that antibody-mediated depletion of platelets can
attenuate vascular permeability and leukocyte infiltration
in an acute lung injury mouse model, via decreased
endothelial cell adhesion molecule expression and me-
diator release [52], and in a cecal ligation and puncture
(CLP) murine model of sepsis, due to a decrease in
both chemokine release and platelet-leukocyte interac-
tions [53]. Consistently, using both platelet depletion
and CD40L-deficient animals, Rahman et al. identified
platelet-derived CD40L as a driving force in the pathologic
recruitment and infiltration of leukocytes into the lung in
the CLP mouse model, thereby aiding in the development
of lung injury and edema [54]. Furthermore, Lapchak
et al. also employed both platelet depletion and CD40- or
CD40L-deficient mouse models of mesenteric ischemia/
reperfusion injury and observed lung damage only when
platelets, CD40, or CD40L were present, whereas platelet-
depleted mice and those deficient in CD40 or CD40L had
a marked absence of vessel damage [55].
In line with this, platelet activation and the CD40/
CD40L axis have also been reported to have induced
vascular permeability in ischemia/reperfusion injury in
the brain [56], as well as other disorders of the CNS,
notably cerebral malaria [19,57,58]. These studies have
taken advantage of both platelet depletion and/or CD40-
or CD40L-deficient mouse models to demonstrate that
CD40L signaling is required for the breakdown of the
BBB and consequential tissue damage. These results are
consistent with our previous findings, and further high-
light the unconventional role of platelet activation and
the subsequent release of sCD40L in the progression of
diseases known to be exacerbated by vascular permeabi-
lity in both the periphery and the CNS.
Antiplatelet therapies for the management of HIV-
associated neuroinflammation
The identification of novel roles for sCD40L in inflam-
mation and illness, such as those described above, has
highlighted the need to develop novel clinical approa-
ches to inhibit this platelet-derived mediator. Traditio-
nally, the therapeutic targeting of sCD40L has presented
quite a challenge due to the co-stimulatory role of this
mediator in both innate and adaptive immunity, as it is
required for B cell class switching during humoral
immune responses. As such, classical treatments such as
cyclosporine A or anti-CD40L monoclonal antibodies
that cannot distinguish between surface-expressed co-
stimulatory CD40L on T cells and soluble platelet-
derived CD40L, can confer immunosuppression, and
therefore are not suitable for use in HAND. However,
the use of antiplatelet agents that can attenuate the
release of sCD40L from platelets, while leaving surface-
expressed co-stimulatory CD40L unaltered, would prevent
the negative effects on the humoral immune response,
and thus represents an attractive alternative therapeutic
strategy with broad implications for a wide range of in-
flammatory disorders. To this end, it is an interesting no-
tion that antiplatelet agents, which are traditionally used
for the management of cardiovascular disease or inflam-
mation in the periphery, could be used to treat neu-
rological disorders. However, this strategy has benefits
that are pleiotropic, in that it would also serve to re-
duce the risk of cardiovascular, thrombotic and other
inflammatory-associated complications that are com-
mon in HIV-infected individuals.
There are currently numerous strategies for targeting
platelet activity, most of which are centered on the use
of aspirin, ADP receptor antagonists and GPIIb-IIIa
(αIIbβ3) antagonists, and they have largely been studied
in the context of cardiovascular disease.
Aspirin
Aspirin has been studied as an antiplatelet agent for de-
cades, and there is an incredible wealth of knowledge on
the clinical utility, as well as the drawbacks, of this drug.
The effects of aspirin are mediated by its attenuation of
prostaglandin synthesis from arachidonic acid, via the ir-
reversible inhibition of cyclooxygenase 1 and 2 (COX-1
and COX-2, respectively) [59]. Interestingly, while as-
pirin is recommended for the management or preven-
tion of numerous thrombotic-associated diseases, such
as acute myocardial infarction, acute ischemia/reperfu-
sion injury and unstable angina [60], aspirin has been
shown to have little or no effect on the surface expres-
sion and subsequent release of CD40L from platelets
[61,62]. Thus, when considered with the results reviewed
herein, it seems aspirin may not be the most ideal candi-
date for use as an adjunctive therapy during HIV infec-
tion. However, it was recently demonstrated in a small
pilot study that low-dose daily aspirin for 1 week can at-
tenuate platelet and immune activation in HIV-infected
individuals [63], further highlighting the potential utility
of aspirin or other antiplatelet therapies to modulate
HIV-induced inflammation.
GPIIb-IIIa antagonists
In contrast to aspirin, GPIIb-IIIa antagonists have been
shown to control levels of sCD40L, which is not surprising
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given that GPIIb-IIIa is known to regulate the release of
sCD40L from the surface of platelets [64]. Currently, three
GPIIb-IIIa antagonists (abciximab, tirofiban and eptifiba-
tide) are approved for clinical use for the treatment of
thrombotic complications, and several reports indicate
that these drugs are efficient at inhibiting the release of
sCD40L from platelets in patients with various forms of
cardiovascular disease [61,65,66]. During platelet aggrega-
tion, fibrinogen binds to GPIIb-IIIa, which can act as a
bridging molecule in the formation of platelet aggregates,
and this can lead to further platelet activation, degranula-
tion and mediator release. Indeed, eptifibatide has also
been found to regulate the expression of P-selectin
on the surface of platelets [61]. Therefore, inhibition
of GPIIb-IIIa not only attenuates the release of sCD40L
from platelets, but also other pro-inflammatory mediators
that are implicated in inflammatory diseases. Heeschen
et al. demonstrated that treating patients suffering from
acute coronary syndromes and have elevated levels of
sCD40L with abciximab reduced the risk of death or myo-
cardial infarction, clearly illustrating the impact that mo-
dulating mediator release from activated platelets can
have on inflammatory diseases [66]. Although relatively
little is currently known about the effects of these drugs
on T and B cell responses, especially in the context of HIV
infection, GPIIb-IIIa is a platelet-specific integrin, sugges-
ting that off-target effects would be minimal.
ADP receptor antagonists
ADP receptor antagonists, such as clopidogrel, have
been implicated in CD40L control in vivo [67], as ADP
is known to induce CD40L surface expression and re-
lease from platelets; however, there is limited evidence
on whether these drugs are able to control CD40L levels
in the context of inflammatory disease. At least one
study found that clopidogrel was able to attenuate plasma
levels of sCD40L in immunosuppressed renal transplant
patients, who are prone to platelet-associated inflamma-
tory complications [68], implying that further studies with
clopidogrel may be warranted for the management of in-
flammation in the context of HIV.
Phosphodiesterase inhibitors
An alternative antiplatelet agent that has been shown to
reduce the activation-induced release of sCD04L from
platelets is dipyridamole [69,70]. Although several mech-
anisms of action have been identified for this drug, the
major way in which it inhibits platelets is via phospho-
diesterase (PDE) inhibition. This ultimately causes the
accumulation of the cyclic nucleotides cAMP and cGMP
within platelets, which exerts an inhibitory effect [71].
Interestingly, PDE inhibitors may have multiple benefits
for HAND in addition to controlling the release of
sCD40L, as it was recently demonstrated that inhibition
of PDE type 5, using the PDE inhibitor gisadenafil, could
restore alterations in HIV Tat-induced cerebrovascular
pathology and changes in cerebral blood flow in a mouse
model of HIV neuroinflammation [72]. Furthermore,
ibudilast, an alternative PDE inhibitor, attenuated Tat-
induced inflammatory responses in a murine microglial
cell line [73] and it has been shown to control the re-
lease of sCD40L from platelets [74]. Taken together,
these results suggest that dipyridamole and other PDE
inhibitors may be extremely beneficial in controlling
HIV-induced inflammation and platelet activation, as
well as neuroinflammation.
Statins
In addition to classical antiplatelet agents, other classes
of drugs, notably statins and glitazones, can modulate
CD40L signaling, and like antiplatelet agents they are
utilized for the management of cardiovascular diseases.
Statins, such as atorvastatin and simvastatin, inhibit
3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA)
reductase (HMGR), which is involved in a crucial step in
the biosynthetic pathway that ultimately gives rise to
cholesterol, and thus, they are used clinically to lower
levels of low-density lipoprotein cholesterol [75]. In
addition, these drugs can reduce the expression of vari-
ous types of pro-inflammatory mediators such as cyto-
kines, chemokines and adhesion molecules [76]. In the
context of CD40L signaling, several studies have re-
vealed that treating endothelial cells with various statins
significantly reduces cytokine-induced expression of CD40
[77-79]. Consistently, Schonbeck et al. demonstrated in a
small pilot study that a 6-month treatment with statins
significantly reduced plasma levels of sCD40L in patients
with atherosclerosis, to similar levels as those of healthy
controls [77]. Furthermore, in a larger study, 110 patients
with familial hypercholesterolemia who received statin
therapy for 2 years had significantly lower plasma sCD40L
concentrations than at baseline [80]. The mechanism by
which statins decrease sCD40L in vivo remains to be de-
termined; however, when considered with the results
presented here, it is likely that statins are capable of
inhibiting platelets, either directly or indirectly. In ad-
dition, the observed ability of statins to decrease CD40 on
endothelial cells would be advantageous for the treatment
of disorders associated with vascular permeability, such
as HAND.
Unfortunately, despite a relatively high number of HIV-
infected patients receiving statins for the control of
hyperlipidemia due to cART [81,82], there is a lack of
reported data on the incidence of HAND and neurological
impairment in the statin-treated HIV-infected population,
as well as the effect of statins on HAND. The potential
utility of these compounds requires further investigation
in the context of HIV.
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Interestingly, statins have been shown to modulate T
cell activation by inhibiting the activation-induced ex-
pression of adhesion molecules [76,83], and they can
downregulate chemokine receptor expression on both B
cells and T cells, thereby dampening inflammatory re-
sponses [83]. This immune-dampening effect of statins
has also been observed in the context of HIV infection
[84]. Furthermore, several reports have demonstrated
that statins can decrease HIV replication by blocking
cellular components that promote infectivity, such as
host membrane proteins acquired by the virus that aid
in attachment and the propagation of infection [85-87].
Although some statins can interact with several antire-
trovirals, others are indicated for HIV-infected individ-
uals for the management of cardiovascular disease [88]
and dyslipidemia [81,82]. Therefore, with proper clinical
assessment and individual consideration, statins may be
safe and well tolerated during treatment for HIV infec-
tion. Collectively, these studies indicate that statins may
be effective at mediating CD40-CD40L signaling, thus
controlling HIV-associated inflammation.
Glitazones
Glitazones are a relatively new class of drugs that are
used to treat type 2 diabetes mellitus and include the
drugs troglitazone and rosiglitazone. A number of small
studies involving patients with diabetes have shown that
several of these drugs can significantly reduce sCD40L
levels [89,90]; however, these drugs have been associated
with hepatotoxicity and an increased risk of cardiovascu-
lar disease, and thus, may not be suitable for use as an
adjunctive therapy in HIV infection.
Glycogen synthase kinase 3β inhibitors
The drugs discussed thus far are fairly classical examples
of antiplatelet agents. While these drugs have obvious
potential implications for the modulation of CD40L sig-
naling beyond their current development as therapeutics
for use in cardiovascular disease, there may be additio-
nal alternative methods for inhibiting platelet activation.
Our group recently revealed the novel antiplatelet acti-
vity of valproic acid (VPA), which limits the release of
sCD40L from platelets. It has promising clinical benefits
for HIV-infected individuals [91] via the decreased
plasma levels of sCD40L. This effect was due to the abi-
lity of VPA to attenuate platelet cytoskeletal rearrange-
ment via inhibition of glycogen synthase kinase 3β
(GSK3β) [92], as rearrangement is a necessary step in
the translocation of CD40L to the surface of platelets for
subsequent cleavage. Similarly, treating platelets with
lithium, another GSK3β inhibitor, also halted cytoskel-
etal rearrangement. The idea of utilizing GSK3β inhibi-
tors in the treatment of HAND is not new [91,93-95];
however, demonstrating that these inhibitors are capable
of modulating platelet mediator release is a novel find-
ing, and this is a desirable characteristic for a candidate
adjunctive therapy for HAND. Indeed, patients receiving
VPA for the treatment of mood disorders and epilepsy
are not immunosuppressed, and hence VPA can modulate
the effects of sCD40L without interfering with surface-
expressed co-stimulatory CD40L. It would be advanta-
geous if further studies could delineate the potential
reduction in thrombotic complications within the peri-
phery in the presence of GSK3β inhibitors.
Our group was the first to report that VPA could ab-
rogate HIV-associated neurotoxicity both in vitro and
in vivo [96,97]. In a controlled pilot patient study, we
demonstrated a trend toward improved cognitive per-
formance, as well as improvements in measures of brain
metabolism [91]. These results highlight the potential
benefits of this drug as an adjunctive therapy for HAND.
Interestingly, some reports have suggested that VPA
may not be well suited for use during HIV infection, as
it is a histone deacetylase inhibitor and therefore may be
capable of activating latent viruses, and thus, increasing
viral replication. However, a small retrospective case–
control study did not find that VPA was associated with
an increase in viral load or HIV disease progression [98].
Moreover, several studies have utilized this characteristic
of VPA in patients receiving this drug in combination
with high doses of cART in an effort to deplete latent
viral reservoirs, with some success [99,100]. Although
there is evidence that VPA may affect the metabolism of
some concomitant medications, it is noteworthy that co-
administration of VPA with efavirenz or lopinavir does
not alter the plasma concentrations of these drugs [101],
thus substantiating the potential efficacy of VPA as an
adjunctive therapy for HIV infection.
Several other reports have noted adverse side effects
associated with long-term use of VPA [102,103]; how-
ever, many of these are case specific and vary depending
on risk factors. The widespread clinical use of this drug
has demonstrated its safety and tolerability, which make
it an attractive therapeutic candidate for the manage-
ment of HAND. Furthermore, the common clinical use
of both VPA and lithium for the treatment of mood dis-
orders and epilepsy, and the relatively low cost of these
drugs, suggests that their implementation for an alterna-
tive use would be met with relative ease. Given the history
of these drugs in the context of HAND [91,93,96,101], it
seems that they, and alternative small molecule inhibitors
of GSK3β, should not be ignored as candidates for ad-
junctive therapies during HIV infection.
Cognitive impairment persists in an estimated 50% of
HIV-infected individuals regardless of cART [38], which
underscores the inability of these therapeutic regimens
to control this aspect of the disease. Moreover, it is now
apparent that these drugs themselves may contribute
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to the development of these disorders via induction
of sCD40L [104]. We found that non-nucleoside reverse
transcriptase inhibitors (NNRTIs) can directly activate
platelets, while other classes of antiretrovirals do not
have this ability. This is an undesirable effect of cART
given that these drugs are already relatively toxic. They
can induce the activation of other cell types in addition to
platelets [105,106], thus exacerbating the already chro-
nically inflamed state. Interestingly, VPA was able to at-
tenuate the release of sCD40L in both NNRTI-treated
isolated human platelets via GSK3β inhibition, and in
HIV-infected individuals receiving cART including a
NNRTI [104]. The advantages of cART in the manage-
ment of HIV infection are undeniable, and thus, these re-
sults further emphasize the value of adjunctive therapies
such as VPA, which can offset the confounding inflamma-
tory effects of cART.
Concluding remarks
In light of the recent observation that more than half of
HIV-infected individuals will develop some form of
neurocognitive impairment regardless of antiretroviral
therapy [38], it seems apparent now more than ever that
novel therapeutic interventions are lacking and in dire
need. Although the implementation of cART has shifted
the severity of HAND to more mild forms, it has obvi-
ously failed to eradicate these disorders, thus implying
that adjunctive therapies are a necessary therapeutic
strategy. Hence, identifying novel targets, such as platelet-
derived sCD40L, is an essential step towards improved
patient care. As with all drugs, there are pros and cons as-
sociated with each of those described here; however, there
is clear evidence to suggest that potential candidates for
the management of HAND remain unexplored and may
prove fruitful in the development of adjunctive therapies
not only for HAND, but also for other pro-inflammatory
HIV-associated illnesses.
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